Feature | Robotic Systems | May 05, 2021

Second Generation Robotic PCI System Performs Well Across Spectrum of Lesion Complexity

Multicenter PRECISION GRX Study showed the Siemens Corpath GRX is safe and effective in variety of real-world lesions

The Corindus CorPath robotic cath lab navigation system allows operators to sit and control the procedure from behind a lead-lined booth, so they do not have to wear heavy aprons during the procedures.  Christoper Baker, M.D., Hoag Memorial Hospital using the system. #SCAI21 #SCAI2021

The Corindus CorPath robotic cath lab navigation system allows operators to sit and control the procedure from behind a lead-lined booth, so they do not have to wear heavy aprons during the procedures.  

May 5, 2021 — A late-breaking study of the Siemens Healthineers Corindus Corpath GRX second-generation cath lab robotic system had high rates of clinical and technical success across the spectrum of lesion complexity. The multicenter PRECISION GRX Study was presented at the Society for Cardiovascular Angiography and Interventions (SCAI) 2021 meeting.

This second generation robotic-assisted percutaneous coronary intervention (PCI) system enables robotic guidance of catheters, guidewires and balloons and stent delivery from a lead-lined cockpit across the room from the patient. The system removes the operators from the radiation field and allows them to precisely navigate the wires using a joystick console and eliminates their need to wear lead, or to stand for the procedures. 

The PRECISION GRX study (NCT 03278301) evaluated the safety and efficacy of CorPath GRX in treating a real-world, all-comers population.

This prospective international multicenter registry study enrolled patients with obstructive coronary artery disease (>70% stenosis) with clinical indications for PCI treated with robotic PCI. The co-primary endpoints were clinical success (final TIMI 3 flow, <30% residual stenosis without in-hospital major adverse cardiac event) and technical success (robotic clinical success without the need for unplanned manual assistance/conversion).

The study enrolled 980 patients (65.4 ±11.6 years; 73.5% male; 1,233 lesions), 31.6% with acute coronary syndrome and 68.8% with ACC/AHA type B2/C lesions at 20 centers (Table). Clinical success was achieved in 97.8 % (955/976) of subjects and 98.1% (1,204/1,227) of lesions treated robotically. Device technical success was achieved in 86.5% (848/980) of subjects and 89.2% (1,100/1,223) of lesions treated robotically. Technical success was higher for type A/B1 lesions as compared to type B2/C lesions (94.5% vs 85%, p<0.001). 

The trial also reported on the robotic guide catheter and wire control and the new Rotate on Retract function, which mimics operator hand-wire manipulations in complex lesions and chronic total occlusions (CTOs). Corindus recently introduced several advanced robotic wire movements to more accurately mimic interventional wire manipulation techniques.  Read more about this new technology.

This study was conducted by the following researchers: Ehtisham Mahmud, M.D., FSCAI, The University of California; Jeffrey M. Schussler, M.D., FSCAI, Baylor University Medical Center; William J. Nicholson, M.D., Emory HealthCare; Tejas M. Patel, M.D., FSCAI, Apex Heart Institute, India; William Lombardi, M.D., University of Washington Medical Center; Frances Wood, M.D., WakeMeds; Adam C. Salisbury, M.D., FSCAI, Saint Luke's Mid America Heart Institute; Srini Potluri, M.D., FSCAI, Baylor Scott and White The Heart Hospital — Plano; and Alexandra J. Lansky, M.D., FSCAI, Yale University.

 

Related Robots in the Cath Lab Content:

VIDEO: Standardizing PCI Through Smart Robotic Procedural Automation

Corindus Launches technIQ 1 Smart Procedural Automation Series for CorPath GRX Cath lab Robotic System

FDA Clears Corindus CorPath GRX for Peripheral Vascular Interventions

VIDEO: Corindus CorPath Robotic PCI System For The Cardiac Cath Lab

Corindus CorPath Used in World's First-in-Human Telerobotic Coronary Intervention

14 Ways to Reduce Radiation Exposure in the Cath Lab

Corindus Seeking Neurovascular Intervention Clearance for CorPath GRX Vascular Robotic System

Innovations Driving the Cath Lab Technology of Tomorrow

Siemens Completes Acquisition of Cath Lab Robotics Vendor Corindus

First Robotic Coronary Angioplasties Performed With Robocath System in Germany

Hoag Performs First Robotic Carotid Artery Stenting on West Coast
 

Find more news from the SCAI 2021 virtual meeting

Related Content

Clinical trial quality data can be derived from national cardiovascular registries, which may change how trials are performed in the future.

Clinical trial quality data can be derived from national cardiovascular registries, which may change how trials are performed in the future. Getty Images

News | Cardiovascular Clinical Studies | June 24, 2021
June 24, 2021 — Data captured in American College of Cardiology (ACC)...
Heavily calcified coronary arteries seen on a CT scan of the heart. Research at the New York Institute of Technology will create blood flow modeling to show the impact of calcium in arteries as part of a project to develop treatments to remove calcium.

Heavily calcified coronary arteries seen on a CT scan of the heart. Research at the New York Institute of Technology will create blood flow modeling to show the impact of calcium in arteries as part of a project to develop treatments to remove calcium. 

News | Cardiovascular Clinical Studies | January 27, 2021
January 27, 2021 — A New York Institute of Technology research te
Hershey's Chocolate display with samples and coco pods at the American College of Cardiology (ACC) 2012 annual meeting. The company was making the case that chocolate can be good for your heart, which is now supported by several studies. Photo by Dave Fornell

Hershey's Chocolate display with samples and coco pods at the American College of Cardiology (ACC) 2012 annual meeting. The company was making the case that chocolate can be good for your heart, which is now supported by several studies. Photo by Dave Fornell

News | Cardiovascular Clinical Studies | July 22, 2020
July 22, 2020 — Eating chocolate at least once a week is linked with a reduced risk of heart disease, according to re
The first 3-D images have been created of an RNA molecule known as "Braveheart" for its role in transforming stem cells into heart cells. Credit: Image courtesy Los Alamos National Laboratory

The first 3-D images have been created of an RNA molecule known as "Braveheart" for its role in transforming stem cells into heart cells. Credit: Image courtesy Los Alamos National Laboratory

News | Cardiovascular Clinical Studies | January 20, 2020
January 20, 2020 — Scientists at Los Alamos and international partners have created the first 3-D images of a special
Top Cardiology New in 2019 From the European Society of Cardioloigy (ESC)
News | Cardiovascular Clinical Studies | December 23, 2019
Environmental and lifestyle issues were popular this year, with pick up from both...
News | Cardiovascular Clinical Studies | November 26, 2019
November 26, 2019 — The University of Connecticut (UConn) Department of Kinesiology and Hartford Healthcare have sele
FDA Issues Final Guidance on Live Case Presentations During IDE Clinical Trials
News | Cardiovascular Clinical Studies | July 10, 2019
The U.S. Food and Drug Administration (FDA) issued the final guidance “Live Case Presentations During Investigational...
Veradigm Partners With American College of Cardiology on Next-generation Research Registries
News | Cardiovascular Clinical Studies | July 03, 2019
The American College of Cardiology (ACC) has partnered with Veradigm, an Allscripts business unit, to power the next...
New FDA Proposed Rule Alters Informed Consent for Clinical Studies
News | Cardiovascular Clinical Studies | November 19, 2018
The U.S. Food and Drug Administration (FDA) is proposing to add an exception to informed consent requirements for...